Upload
others
View
7
Download
0
Embed Size (px)
Citation preview
2/16/2021
1
1All Content © Immucor
2All Content © Immucor
Welcome!
Enter Fullscreen Mode
Exit Fullscreen Mode
Show Sidebar Menu
Hide Sidebar Menu
3All Content © Immucor
Want to Pose a Question to the Speaker?
2/16/2021
2
4All Content © Immucor
Having Technical Difficulties?
•For an optimal experience, Livestorm recommends using Google Chrome, Firefox or Opera• Internet Explorer is not recommended•You may experience some delays audio/visual (15 seconds)
•Test your connection here:https://app.livestorm.co/connectivity-test
5All Content © Immucor
Having Technical Difficulties?
2021 Webinar Schedule
Link to register: https://app.livestorm.co/immucor
Coming Soon!
Text WEBINARto 47177
2/16/2021
3
7All Content © Immucor
learn.immucor.com
Text LEARN
to 47177
8All Content © Immucor
learn.immucor.com
Text LEARN
to 47177
9All Content © Immucor
Continuing Education
• PACE, Florida and California DHS
• 1.0 Contact Hours
• Each attendee must register to receive CE at:https://www.surveymonkey.com/r/AntibodyScreen
• Registration deadline is 5 March 2021
• Certificates will be sent via email only to those who have registered 19 March 2021
2/16/2021
4
10All Content © Immucor 10
Antibody Detection & Crossmatch Testing:What? When? Why?
11All Content © Immucor
Objectives
• Discuss the purpose antibody detection testing
• Review techniques for antibody detection testing
• Examine reagents used in antibody detection and crossmatch including potentiators and reagent red blood cells
• Compare antibody detection testing to crossmatch testing
12All Content © Immucor
Terminology
Antibody Detection Test
VS
Antibody Screen Test
2/16/2021
5
13All Content © Immucor
Why Antibody Detection Testing?
• After determining ABO/Rh, we want to know:• Is there already a defense mechanism in place to attack a
foreign invader?• If there is a defense mechanism in place, should it end up in
a foreign situation?
• To solve both questions, in the transfusion medicine arena, we need to perform an antibody detection test.
14All Content © Immucor
Why Antibody Detection Testing?
• 1-2% of patients have unexpected alloantibodies1
• 20-50% of transfusion dependent patients have unexpected alloantibodies
15All Content © Immucor
A History2…
• 1960s: Full antiglobulin crossmatch• In the event of incompatible crossmatch,
• Continue crossmatching, rather than identifying the antibody
2/16/2021
6
16All Content © Immucor
A History2…
• Initial intent of antibody screen:• Detect anti-D in serum of pregnant women• And ‘other’ antibodies then either unknown or consider unimportant
• Source of screening red cells:• Collected fresh specimens from staff members.• Knickerbocker Biosales was the 1st to offer commercial screen cells.
17All Content © Immucor
Screen VS Crossmatch
Full Antiglobulin
Screen+
Full Antiglobulin Crossmatch
18All Content © Immucor
Publications
Publication Article Focus
The Type and Screen: a Safe Alternative and Supplement in Selected Surgical Procedures6
The Risk of Abbreviating the Major Crossmatch in Urgent or Massive Transfusion7
Sensitivity of antibody screen test
The Implementation of Antibody Screening in Pre-transfusion testing for patient safety in Jakarta Blood Transfusion Unit8
Frequency of ‘false negative’ crossmatches
Time of Attention of Concentrate Red Blood Cells Through Type & Screen – Abbreviated Cross Test in a Blood Bank of a Hospital Emergency Center in Lima, Peru9
Turn-around-time for antibody screen test
2/16/2021
7
19All Content © Immucor 19
Methods for Antibody Detection Testing
20All Content © Immucor
Antibody Detection Methods
COLD(Room
Temperature)
Agglutinating Coating
WARM(37 C)
Anti-M, -N; -Lea, -Leb, -P1, -I, -I, -H, -IH
Anti-D, -C, -c, -E, -e; -K; -Jka, -Jkb; -Fya, -Fyb; -S, -s
Usually naturally occurring
Generally unwanted
Most Frequent Reaction Phase
for Commonly Encountered Antibodies1
21All Content © Immucor
Antigen Antibody Reactions
• Ag/Ab reactions must be visualized to be interpreted properly
• Can be done by:• Agglutination (tube or column)• Adherence (solid phase)• Hemolysis• Precipitation• Color change (Absorbance, Florescence)
2/16/2021
8
22All Content © Immucor 22
Adherence
23All Content © Immucor
Adherence
24All Content © Immucor
Adherence
2/16/2021
9
25All Content © Immucor 25
Agglutination
26All Content © Immucor
Agglutination
Antibody uptake or “Sensitization”
Phase I
27All Content © Immucor
Agglutination
Factors Affecting Sensitization3
• Incubation Time
• Temperature
• pH
• Ionic strength
• Antigen distribution
• Ratio of antigen to antibody
2/16/2021
10
28All Content © Immucor
Agglutination
Can be either IgG or IgM
Visible agglutination as red blood cells bind into clumps
Phase II
29All Content © Immucor
Agglutination
Factors Affecting Binding4
• Positively charged molecules
• Location/position of antigen
• Zeta potential
30All Content © Immucor
Agglutination
Zeta Potential
2/16/2021
11
31All Content © Immucor
Comparison of Agglutination & Solid Phase
MethodSample
Volume (µL)
Red Cell Surface Area
(mm2)
Sample to Cell Ratio
(µL/mm2)
Solid Phase 25* 66.4 .38
Column Agglutination 25 598 .04
Tube Agglutination 100 2244 .04
32All Content © Immucor 32
Potentiators5
33All Content © Immucor
How do potentiators work?
• Protein/ Colloid Media• Increase dielectric constant which reduces zeta potential• Examples: albumin, PEG, polybrene
• Low Ionic Strength Media• Decreases ionic strength which reduces zeta potential• Examples: LISS
2/16/2021
12
34All Content © Immucor
Low Ionic Strength Solutions (LISS)
• 0.2% NaCl
• Enhance antibody uptake by reducing the zeta potential
• Reduce incubation time
• Dependent on serum:cell ratio
35All Content © Immucor
Polyethylene Glycol (PEG)
• H20-soluble polymer
• Removes water & forces sensitized red blood cells closer together by concentration
• Considered more sensitive than LISS for the detection of clinically significant antibodies
• Can be used in adsorption procedures and with eluates.
36All Content © Immucor 36
Reagent Red Blood Cells (red blood cells)
2/16/2021
13
37All Content © Immucor
Reagent red blood cells
• Genes can be either Homozygous or Heterozygous• ie. Fy*A / Fy*A or FY*A / FY*B
• Antigens show Dosage:• Double dose Fy(a+b-) or Single dose Fy(a+b+)
• Homozygous genes produces double dose antigens.
• Heterozygous genes produce one dose of each antigen for each gene present.
38All Content © Immucor
Reagent red blood cells, Pooled
39All Content © Immucor
Reagent red blood cells, 2-cell
2/16/2021
14
40All Content © Immucor
Reagent red blood cells, 3-cell
41All Content © Immucor
Reagent red blood cells
Pooled Cell 2 - Cell 3 - Cell
Contains a D- cell no no yes
Sensitivity by Ag sites < sensitive >pooled, <3-cell Best
Guaranteed JK & FY double dose no maybe yes
42All Content © Immucor 42
Publications
2/16/2021
15
43All Content © Immucor
Screen VS Crossmatch
The Type and Screen: a Safe Alternative and Supplement in Selected Surgical Procedures6
L I Boral, J B Henry, Transfusion. Mar-Apr 1977.
“The type and screen can be shown to be 99.99% effective in preventing the transfusion of incompatible blood.”
44All Content © Immucor
Screen VS Crossmatch
The Risk of Abbreviating the Major Crossmatch in Urgent or Massive Transfusion7
H A Oberman, B A Barnes, B A Friedman, Transfusion. Mar-Apr 1978.
“Issuance of blood in urgent situations after an “immediate spin” phase of the crossmatch, for patients whose red blood cells have been typed, and whose serums have been screened for unexpected antibodies, has a low level of risk.
45All Content © Immucor
Screen VS Crossmatch
The Implementation of Antibody Screening in Pre-transfusion testing for patient safety in Jakarta Blood Transfusion Unit8
M Maryunis, P Rini, NK Ritchie and S Salim, ISBT Abstract. 2015.
• 65,045 samples tested• 387 positive antibody screen test
• 79 positive crossmatch• 308 false negative crossmatch
2/16/2021
16
46All Content © Immucor
Screen VS Crossmatch
Time of Attention of Concentrate Red Blood Cells Through Type & Screen – Abbreviated Cross Test in a Blood Bank of a Hospital Emergency Center in Lima, Peru9
L Fernandez Bolivar1, A Sagastegui Soto2, E Santiago3 and B Cordova Cervantes2, ISBT Abstract. 2020.
• 7,438 requests for blood• 29.1% available within 5 min• 60.2% available within 30 min• 85.9% available within 60 min
47All Content © Immucor
Summary
• Detection of unexpected antibodies is important for patient safety.
• Reagent red blood cells are intentionally selected
• Potentiators can be used to enhance antibody detection
• The use of automation allows for fast-turn-around time for type, screen and crossmatch testing.
48All Content © Immucor
References
1. Moulds, M. (2010). Guidelines for Antibody Identification. American Association of Blood Banks.
2. Reid, S. R. P. M. (2016). Bloody Brilliant! A History of Blood Groups and Blood Groupers. Bethesda, Maryland: AABB Press.
3. Coombs RRA, Race RR and Mourant AE. A new test for the detection of weak and “incomplete” Rh agglutinins. British Journal of Experimental Pathology 1945 Aug; 26(4): 255–266
4. N. C. Hughes-Jones, M.A. B.M. B.Ch. Ph.D., Nature of the Reaction between Antigen and Antibody, British Medical Bulletin, Volume 19, Issue 3, September 1963, Pages 171–177.
5. Harmening, D. M. (2018). Modern blood banking & transfusion practices (7th ed.). Philadelphia, PA: F.A. Davis Company.
6. Boral LI, Henry JB. The type and screen: A safe alternative and supplement in selected surgical procedures. Transfusion 1977;17:163-8
7. Oberman, H.A. , Barnes, B.A. , Friedman, B.A. The risk of abbreviating the major crossmatch in urgent or massive transfusion. Transfusion 1978; 18: 137–141.
8. M. Maryunis, P. Rini, N.K. Ritchie, and S Salim. (2015). The Implementation of Antibody Screening in Pre-transfusion testing for patient safety in Jakarta Blood Tranfusion Unit. Vox San, 109 S2, 72.
9. L. Fernandez Bolivar, A. Sagastegui Soto, E. Santiago, B. Cordova Cervantes. (2020). Time of Attention of Concentrate Red Blood Cells Through Type & Screen – Abbreviated Cross Test in a Blood Bank of a Hospital Emergency Center in Lima, Peru. Vox Sang, 115 S1, 101–102.
Boral LI, Henry JB. The type and screen: A safe alternative and supplement in selected surgical procedures. Transfusion 1977;17:163-8.Boral LI, Henry JB. The type and screen: A safe alternative and supplement in selected surgical procedures. Transfusion 1977;17:163-8.
2/16/2021
17
49All Content © Immucor
Questions?
50All Content © Immucor
Continuing Education
• PACE, Florida and California DHS
• 1.0 Contact Hours
• Each attendee must register to receive CE at:https://www.surveymonkey.com/r/AntibodyScreen
• Registration deadline is 5 March 2021
• Certificates will be sent via email only to those who have registered 19 March 2021
2021 Webinar Schedule
Link to register: https://app.livestorm.co/immucor
Coming Soon!
Text WEBINARto 47177
2/16/2021
18
52All Content © Immucor
53All Content © Immucor
54All Content © Immucor
Thank you!